Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Nabriva Therapeutics AG (NBRV)

Add NBRV Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/3/2016 8:04:16 PM - Followers: 1 - Board type: Free - Posts Today: 0

Nabriva Therapeutics AG Leberstrasse 20 Vienna, 1110 Austria Phone: 43 1 740 93 0 Fax: 43 1 740 93 1900 Website: Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections. The company is developing intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia; and intends to develop lefamulin for additional indications other than pneumonia. It is also developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics AG in 2007. Nabriva Therapeutics AG was incorporated in 2005 and is headquartered in Vienna, Austria.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NBRV News: Current Report Filing (8-k) 08/21/2017 04:08:36 PM
NBRV News: Proxy Statement (definitive) (def 14a) 08/18/2017 04:19:38 PM
NBRV News: Current Report Filing (8-k) 08/11/2017 04:08:06 PM
NBRV News: Notice of Effectiveness (effect) 08/11/2017 06:02:04 AM
NBRV News: Current Report Filing (8-k) 08/07/2017 11:54:09 AM
#1   NBRV bearish 7.38 stocktrademan 06/03/16 08:04:16 PM